Scarica l'app Stockscreener
6.07
1.17%
0.07
Dopo l'orario di chiusura:
6.07
Precedente Chiudi:
$6.00
Aprire:
$5.956
Volume 24 ore:
6,019
Relative Volume:
0.02
Capitalizzazione di mercato:
$68.46M
Reddito:
$800.00K
Utile/perdita netta:
$-45.07M
Rapporto P/E:
-1.1544
EPS:
-5.2583
Flusso di cassa netto:
$-52.08M
1 W Prestazione:
+2.88%
1M Prestazione:
+7.43%
6M Prestazione:
-10.34%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.87
$6.07
Intervallo di 1 settimana:
$5.56
$6.07
Portata 52W:
$3.94
$17.96
Imagenebio Inc Stock (IMA) Company Profile
Nome
Imagenebio Inc
Settore
Industria
Telefono
857-343-8292
Indirizzo
12526 HIGH BLUFF DRIVE, SAN DIEGO
Compare IMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
6.07 | 67.67M | 800.00K | -45.07M | -52.08M | -5.2583 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Imagenebio Inc Stock (IMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-25 | Ripresa | Wedbush | Underperform |
| 2025-10-24 | Iniziato | Leerink Partners | Outperform |
Imagenebio Inc Borsa (IMA) Ultime notizie
ImageneBio Appoints Matt Robbins as General Counsel - The Manila Times
Enterprise value to revenue forward of ImageneBio, Inc. – NASDAQ:IMA - TradingView
Enterprise value to EBIT forward of ImageneBio, Inc. – BOATS:IMA - TradingView
IMA Stock Surges 24%, Breaks 50-DMA For First Time Since February – What's Driving The Rally? - Stocktwits
ImageneBio (IMA) prospectus supplement registers 2.5M shares for resale - Stock Titan
Price to earnings forward of ImageneBio, Inc. – NASDAQ:IMA - TradingView
Price to book forward of ImageneBio, Inc. – NASDAQ:IMA - TradingView
Price to sales forward of ImageneBio, Inc. – NASDAQ:IMA - TradingView
Price to sales forward of ImageneBio, Inc. – BOATS:IMA - TradingView
Price to earnings forward of ImageneBio, Inc. – BOATS:IMA - TradingView
Enterprise value to EBITDA forward of ImageneBio, Inc. – BOATS:IMA - TradingView
ImageneBio Announces Upcoming Transition in Financial Leadership - TipRanks
Imagenebio (NASDAQ: IMA) finance chief Robert Lally to step down - Stock Titan
Imagenebio, Inc. Announces Resignation of Robert Lally as Senior Vice President of Finance and Operations, Effective July 22, 2026 - marketscreener.com
ImageneBio, Inc. Actuals & Estimates (NASDAQ:IMA) - TradingView
IMA Forecast — Price Target — Prediction for 2027 - TradingView
ImageneBio Ord Shs (IMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ImageneBio Ord Shs (IMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ImageneBio Shareholders Back Directors and Governance Proposals - The Globe and Mail
ImageneBio stockholders approve equity plan amendment and elect directors By Investing.com - Investing.com India
ImageneBio Ord Shs (IMA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ImageneBio stockholders approve equity plan amendment and elect directors - Investing.com UK
ImageneBio Ord Shs (IMA) Institutional Confidence - TradingKey
ImageneBio Ord Shs (IMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ImageneBio Inc. (IMA) Slips 1.58% as Stock Nears Critical Support LevelFloat Adjusted Cap - newsline.com
IMA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Ramps Up R&DGuidance Downgrade Alert - dars.gov.et
IMA Q1 2026 Earnings: Wider-than-expected loss as EPS misses estimatesOne-Time Loss Impact - newsline.com
IMA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineNew Analyst Coverage - newsline.com
IMA Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing R&D InvestmentsDividend Earnings Report - newsline.com
ImageneBio Inc. (IMA) Q1 2026 Earnings: EPS Misses Estimates Amid Development Stage StatusMargin Expansion Trends - dars.gov.et
Ikena Oncology Inc stock (US4517401090): trading in United States halted as ImageneBio merger progre - AD HOC NEWS
Imagenebio Inc. Live Share Prices and Trades. IMA.US Live Streaming Share Prices. - London South East
IMA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Reports Wider LossRevenue Miss Report - dars.gov.et
ImageneBio (IMA) Holds Steady at $5.92 as Traders Eye Support and ResistanceMFI Oversold - dars.gov.et
ImageneBio CEO to present at 2026 Jefferies Global Healthcare Conference in New York - Pluang
ImageneBio CEO to speak at New York Jefferies healthcare conference June 4 - Stock Titan
IMA stock surges 24%, breaks 50-DMA for first time since February – what's driving the rally? - MSN
IMAImageneBio Inc Stock Price and Quote - Finviz
ImageneBio (IMA) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineCommunity Breakout Alerts - Newser
ImageneBio (IMA) Q1 2026 Results Fall Short — EPS $-0.95, Revenue $N/AExpert Stock Picks - Newser
ImageneBio (IMA) Q1 2026 Stumbles — EPS $-0.95 Misses TargetReturn On Assets - Newser
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade - MSN
ImageneBio $30 million private placement ignites stock - MSN
Imagenebio Inc Azioni (IMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Imagenebio Inc Azioni (IMA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bonita David P | Director |
Jul 25 '25 |
Buy |
29.90 |
83,611 |
2,499,969 |
287,885 |
| Stampacchia Otello | Director |
Jul 25 '25 |
Buy |
29.90 |
267,556 |
7,999,924 |
454,982 |
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):